Evolent Health (EVH): Schedule 13G/A Amendment No. 2 discloses that Eventide Asset Management and affiliated reporting persons beneficially own 6,292,511 shares of Class A common stock, representing 5.4% of the class as of September 30, 2025.
Eventide reports sole voting and dispositive power over 6,292,511 shares. Finny Kuruvilla, M.D., Ph.D., and Robin C. John report shared voting and dispositive power over 6,292,511 shares. Holdings are allocated across Eventide Gilead Fund (3,900,000; 3.3%), Eventide Healthcare & Life Sciences Fund (2,356,913; 2.0%), Eventide Small Cap ETF (88; 0.0%), and separately managed accounts (35,510; 0.1%). The filing certifies the securities are held in the ordinary course and not for the purpose of changing or influencing control.
Positive
None.
Negative
None.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 2)
Evolent Health, Inc.
(Name of Issuer)
Class A Common Stock, par value $0.01 per share
(Title of Class of Securities)
30050B101
(CUSIP Number)
09/30/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
30050B101
1
Names of Reporting Persons
Eventide Asset Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
6,292,511.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
6,292,511.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,292,511.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
CUSIP No.
30050B101
1
Names of Reporting Persons
Finny Kuruvilla, M.D. Ph. D.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,292,511.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,292,511.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,292,511.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP No.
30050B101
1
Names of Reporting Persons
Robin C. John
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
6,292,511.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
6,292,511.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
6,292,511.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.4 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Evolent Health, Inc.
(b)
Address of issuer's principal executive offices:
1812 North Moore St, Suite 1705, Arlington, VA 22209
Item 2.
(a)
Name of person filing:
(i) Eventide Asset Management, LLC ("Eventide")
(ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla")
(iii) Robin C. John ("John")
(b)
Address or principal business office or, if none, residence:
Eventide, Kuruvilla and John:
One International Place, Suite 4210
Boston, Massachusetts 02110
(c)
Citizenship:
Eventide: Delaware
Kuruvilla: United States
John: United States
(d)
Title of class of securities:
Class A Common Stock, par value $0.01 per share
(e)
CUSIP No.:
30050B101
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
(i) Eventide: 6,292,511
(ii) Kuruvilla: 6,292,511
(iii) John: 6,292,511
(b)
Percent of class:
(i) Eventide: 5.4%
(ii) Kuruvilla: 5.4%
(iii) John: 5.4%
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
As of September 30, 2025, Eventide Asset Management, LLC, a Delaware limited liability company located at One International Place, Suite 4210, Boston, Massachusetts 02110, is the beneficial owner of 6,292,511 shares of the Issuer's Common Stock by virtue of being the investment adviser to Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, and Eventide Small Cap ETF, which are registered investment companies, and Eventide separately managed accounts, (the "Accounts").
As of September 30, 2025, the Eventide Gilead Fund held 3,900,000 shares of the Issuer's Common Stock, representing 3.3% of the Issuer's outstanding Common Stock, the Eventide Healthcare & Life Sciences Fund held 2,356,913 shares of the Issuer's Common Stock, representing 2.0% of the Issuer's outstanding Common Stock, the Eventide Small Cap ETF held 88 shares of the Issuer's Common Stock, representing 0.0% of the Issuer's outstanding Common Stock, and Eventide's separately managed accounts held 35,510 shares of the Issuer's Common Stock, representing 0.1% of the Issuer's outstanding Common Stock, which together represents 5.4% of the Issuer's outstanding Common Stock.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Eventide Asset Management, LLC
Signature:
/s/ Peter J. Luiso
Name/Title:
Peter J. Luiso, General Counsel
Date:
11/14/2025
Finny Kuruvilla, M.D. Ph. D.
Signature:
/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:
Finny Kuruvilla, M.D., Ph. D.
Date:
11/14/2025
Robin C. John
Signature:
/s/ Robin C. John
Name/Title:
Robin C. John
Date:
11/14/2025
Exhibit Information
EXHIBIT 1
WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;
NOW, THEREFORE, the parties hereto agree as follows:
Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.
Eventide Asset Management, LLC
Date: November 14, 2025
By: /s/ Peter J. Luiso
Name: Peter J. Luiso
Title: General Counsel
Date: November 14, 2025
Finny Kuruvilla, M.D., Ph. D.
By: /s/ Finny Kuruvilla, M.D., Ph. D.
Name: Finny Kuruvilla, M.D., Ph. D.
Date: November 14, 2025
Robin C. John
By: /s/ Robin C. John
Name: Robin C. John
Eventide reports beneficial ownership of 6,292,511 shares of Evolent Health Class A common stock, representing 5.4% of the class as of September 30, 2025.
Who are the reporting persons in the EVH Schedule 13G/A?
The reporting persons are Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John.
How are EVH shares allocated across Eventide vehicles?
Eventide Gilead Fund 3,900,000 (3.3%); Eventide Healthcare & Life Sciences Fund 2,356,913 (2.0%); Eventide Small Cap ETF 88 (0.0%); separately managed accounts 35,510 (0.1%).
What voting and dispositive powers are reported?
Eventide has sole voting and dispositive power over 6,292,511 shares. Kuruvilla and John have shared voting and dispositive power over 6,292,511 shares.
Is this a passive ownership filing for EVH?
Yes. The certification states the securities are held in the ordinary course and not for the purpose of changing or influencing control.
What is the CUSIP and class of EVH securities referenced?
The filing covers Class A common stock with CUSIP 30050B101.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
You have made too many password recovery requests. Please try again tomorrow.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
